<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36980810</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4425</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>21</Day></PubDate></JournalIssue><Title>Genes</Title><ISOAbbreviation>Genes (Basel)</ISOAbbreviation></Journal><ArticleTitle>Association of the <i>STAT4</i> Gene rs7574865 Polymorphism with IFN-&#x3b3; Levels in Patients with Systemic Lupus Erythematosus.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">537</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/genes14030537</ELocationID><Abstract><AbstractText>STAT4 plays an important role in disease activity in SLE patients. STAT4 particles have the capacity to activate the transcription of genes associated with the production of TH1 and Th17 lymphocytes, with a greater predominance on the production of IFN-&#x3b3; and IL-17A. The presence of variants in <i>STAT4</i> genes has a major impact on the generation of autoimmunity. However, there are few studies evaluating the impact of these variants on the production of proinflammatory cytokines such as IFN-&#x3b3; and IL-17A. Methods-A case-control study was carried out with 206 Mexican mestizo patients residing in Western Mexico with a diagnosis of SLE and a group of 80 patients without autoimmune diseases was captured to determine the cut-off point for high IFN-&#x3b3; levels. In this study, SLE patients with high IFN-&#x3b3; levels were considered as cases (cut-off &gt; 15.6 pg/mL), and SLE patients with normal IFN-&#x3b3; levels were considered as controls (cut-off &#x2264; 15.6 pg/mL). Disease activity was identified from the systemic lupus erythematosus disease activity index (SLEDAI). For the determination of levels of cytokines IFN-&#x3b3;, IL-12, and IL17A, commercial ELISA kits were used. Genotyping of STAT4 rs7574865 (G &gt; T) was performed by quantitative polymerase chain reaction (qPCR) using TaqMan probes. Results-The patients with SLE had a median age of 45 years with a range of disease duration from 4 years to 18 years; 45.6% were identified as having disease activity. In this sample, we identified a high IFN-&#x3b3; prevalence of 35.4%. The levels of IFN-&#x3b3; were higher in the patients with genotype TT than GG. We found that TT genotype conferred a higher risk of high IFN-&#x3b3; when compared to the GG and GT genotypes. Conclusions-In this study, we identified that the polymorphic genotype TT of the <i>STAT4</i> gene rs7574865 polymorphism is associated with increased levels of IFN-&#x3b3;. However, its strength of association was weak, so complementary studies are needed to evaluate its impact on SLE patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Esparza Guerrero</LastName><ForeName>Yussef</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-6871-9052</Identifier><AffiliationInfo><Affiliation>Programa de Doctorado en Farmacolog&#xed;a, Departamento de Fisiolog&#xed;a, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vazquez Villegas</LastName><ForeName>Maria Luisa</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Departamento de Epidemiolog&#xed;a, Unidad de Medicina Familiar No. 4, Instituto Mexicano del Seguro Social (IMSS), Guadalajara 44340, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Regional de Investigaci&#xf3;n en Salud P&#xfa;blica, Programa de Doctorado y Coordinaci&#xf3;n del Programa de Doctorado en Salud P&#xfa;blica, Departamento de Salud P&#xfa;blica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nava Valdivia</LastName><ForeName>Cesar Arturo</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Departamento de Microbiolog&#xed;a y Patolog&#xed;a, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ponce Guarneros</LastName><ForeName>Juan Manuel</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0001-5035-3347</Identifier><AffiliationInfo><Affiliation>Departamento de Fisiolog&#xed;a, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perez Guerrero</LastName><ForeName>Edsaul Emilio</ForeName><Initials>EE</Initials><Identifier Source="ORCID">0000-0002-0007-1824</Identifier><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n en Ciencias Biom&#xe9;dicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez Ramirez</LastName><ForeName>Eli Efrain</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Programa de Doctorado en Farmacolog&#xed;a, Departamento de Fisiolog&#xed;a, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramirez Villafa&#xf1;a</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Departamento de Fisiolog&#xed;a, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Terap&#xe9;utica Experimental y Cl&#xed;nica, Departamento de Fisiolog&#xed;a, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Contreras Haro</LastName><ForeName>Betsabe</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Unidad de Investigaci&#xf3;n Biom&#xe9;dica 02, UMAE, Hospital de Especialidades, Centro M&#xe9;dico Nacional de Occidente, IMSS, Guadalajara 44349, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Ciencias Biom&#xe9;dicas, Centro Universitario de Tonal&#xe1;, Universidad de Guadalajara, Guadalajara 45400, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez Hernandez</LastName><ForeName>Alejandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Programa de Doctorado en Farmacolog&#xed;a, Departamento de Fisiolog&#xed;a, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cardona Mu&#xf1;oz</LastName><ForeName>Ernesto German</ForeName><Initials>EG</Initials><Identifier Source="ORCID">0000-0001-7868-667X</Identifier><AffiliationInfo><Affiliation>Instituto de Terap&#xe9;utica Experimental y Cl&#xed;nica, Departamento de Fisiolog&#xed;a, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nu&#xf1;o Arana</LastName><ForeName>Ismael</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-0386-1004</Identifier><AffiliationInfo><Affiliation>Departamento de Ciencias Biom&#xe9;dicas, Centro Universitario de Tonal&#xe1;, Universidad de Guadalajara, Guadalajara 45400, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallardo Moya</LastName><ForeName>Sergio Gabriel</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Programa de Doctorado en Farmacolog&#xed;a, Departamento de Fisiolog&#xed;a, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Celis</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Instituto Regional de Investigaci&#xf3;n en Salud P&#xfa;blica, Programa de Doctorado y Coordinaci&#xf3;n del Programa de Doctorado en Salud P&#xfa;blica, Departamento de Salud P&#xfa;blica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez Lopez</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-6517-6344</Identifier><AffiliationInfo><Affiliation>Programa de Doctorado en Farmacolog&#xed;a, Departamento de Fisiolog&#xed;a, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Regional de Investigaci&#xf3;n en Salud P&#xfa;blica, Programa de Doctorado y Coordinaci&#xf3;n del Programa de Doctorado en Salud P&#xfa;blica, Departamento de Salud P&#xfa;blica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gamez Nava</LastName><ForeName>Jorge Ivan</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Programa de Doctorado en Farmacolog&#xed;a, Departamento de Fisiolog&#xed;a, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Regional de Investigaci&#xf3;n en Salud P&#xfa;blica, Programa de Doctorado y Coordinaci&#xf3;n del Programa de Doctorado en Salud P&#xfa;blica, Departamento de Salud P&#xfa;blica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salda&#xf1;a Cruz</LastName><ForeName>Ana Miriam</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Instituto de Terap&#xe9;utica Experimental y Cl&#xed;nica, Departamento de Fisiolog&#xed;a, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Genes (Basel)</MedlineTA><NlmUniqueID>101551097</NlmUniqueID><ISSNLinking>2073-4425</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020381">Interleukin-17</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C494090">STAT4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050797">STAT4 Transcription Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="Y">Interferon-gamma</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020381" MajorTopicYN="N">Interleukin-17</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050797" MajorTopicYN="Y">STAT4 Transcription Factor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IFN-gamma</Keyword><Keyword MajorTopicYN="N">STAT4</Keyword><Keyword MajorTopicYN="N">polymorphism</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>29</Day><Hour>1</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36980810</ArticleId><ArticleId IdType="pmc">PMC10048585</ArticleId><ArticleId IdType="doi">10.3390/genes14030537</ArticleId><ArticleId IdType="pii">genes14030537</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tsokos G.C. Systemic Lupus Erythematosus. N. Engl. J. Med. 2011;365:2110&#x2013;2121. doi: 10.1056/NEJMra1100359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1100359</ArticleId><ArticleId IdType="pubmed">22129255</ArticleId></ArticleIdList></Reference><Reference><Citation>Zian Z., Maamar M., El Aouni M., Barakat A., Nourouti N.G., El Aouad R., Arji N., Mechita M.B. Immunological and Clinical Characteristics of Systemic Lupus Erythematosus: A Series from Morocco. BioMed Res. Int. 2018;2018:1&#x2013;5. doi: 10.1155/2018/3139404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/3139404</ArticleId><ArticleId IdType="pmc">PMC6186365</ArticleId><ArticleId IdType="pubmed">30363993</ArticleId></ArticleIdList></Reference><Reference><Citation>Obri&#x219;c&#x103; B., Sorohan B., Tu&#x21b;&#x103; L., Ismail G. Advances in Lupus Nephritis Pathogenesis: From Bench to Bedside. Int. J. Mol. Sci. 2021;22:3766. doi: 10.3390/ijms22073766.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22073766</ArticleId><ArticleId IdType="pmc">PMC8038540</ArticleId><ArticleId IdType="pubmed">33916456</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano M., Iwasaki Y., Fujio K. Transcriptomic studies of systemic lupus erythematosus. Inflamm. Regen. 2021;41:11. doi: 10.1186/s41232-021-00161-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41232-021-00161-y</ArticleId><ArticleId IdType="pmc">PMC8033719</ArticleId><ArticleId IdType="pubmed">33836832</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S.Y., Boisson-Dupuis S., Chapgier A., Yang K., Bustamante J., Puel A., Picard C., Abel L., Jouanguy E., Casanova J.L. Inborn errors of interferon (IFN)-mediated immunity in humans: Insights into the respective roles of IFN-&#x3b1;/&#x3b2;, IFN-&#x3b3;, and IFN-&#x3bb; in host defense. Immunol. Rev. 2008;226:29&#x2013;40. doi: 10.1111/j.1600-065X.2008.00698.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2008.00698.x</ArticleId><ArticleId IdType="pubmed">19161414</ArticleId></ArticleIdList></Reference><Reference><Citation>Balkwill F.R. Interferons. Lancet. 1989;333:1060&#x2013;1063. doi: 10.1016/S0140-6736(89)92455-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(89)92455-0</ArticleId><ArticleId IdType="pubmed">2469921</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley L.M., Dalton D.K., Croft M. A direct role for IFN-gamma in regulation of Th1 cell development. J. Immunol. 1996;157:1350&#x2013;1358. doi: 10.4049/jimmunol.157.4.1350.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.157.4.1350</ArticleId><ArticleId IdType="pubmed">8759714</ArticleId></ArticleIdList></Reference><Reference><Citation>Baudino L., da Silveira S.A., Nakata M., Izui S. Molecular and cellular basis for pathogenicity of autoantibodies: Lessons from murine monoclonal autoantibodies. Springer Semin. Immunopathol. 2006;28:175&#x2013;184. doi: 10.1007/s00281-006-0037-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-006-0037-0</ArticleId><ArticleId IdType="pubmed">16953439</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacotte S., Decossas M., le Coz C., Brun S., Muller S., Dumortier H. Early Differentiated CD138highMHCII+IgG+ Plasma Cells Express CXCR3 and Localize into Inflamed Kidneys of Lupus Mice. PLoS ONE. 2013;8:e58140. doi: 10.1371/journal.pone.0058140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0058140</ArticleId><ArticleId IdType="pmc">PMC3592892</ArticleId><ArticleId IdType="pubmed">23520491</ArticleId></ArticleIdList></Reference><Reference><Citation>Harigai M., Kawamoto M., Hara M., Kubota T., Kamatani N., Miyasaka N. Excessive Production of IFN-&#x3b3; in Patients with Systemic Lupus Erythematosus and Its Contribution to Induction of B Lymphocyte Stimulator/B Cell-Activating Factor/TNF Ligand Superfamily-13B. J. Immunol. 2008;181:2211&#x2013;2219. doi: 10.4049/jimmunol.181.3.2211.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.181.3.2211</ArticleId><ArticleId IdType="pubmed">18641361</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Crisp&#xed;n J.C., Tsokos G.C. Interleukin-17 and systemic lupus erythematosus: Current concepts. Clin. Exp. Immunol. 2009;157:209&#x2013;215. doi: 10.1111/j.1365-2249.2009.03944.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2009.03944.x</ArticleId><ArticleId IdType="pmc">PMC2730846</ArticleId><ArticleId IdType="pubmed">19604260</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D., Guo B., Wu H., Tan L., Chang C., Lu Q. Interleukin-17 in systemic lupus erythematosus: A comprehensive review. Autoimmunity. 2015;48:353&#x2013;361. doi: 10.3109/08916934.2015.1037441.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08916934.2015.1037441</ArticleId><ArticleId IdType="pubmed">25894789</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X., Li J., Fu M., Zhao X., Wang W. The JAK/STAT signaling pathway: From bench to clinic. Signal Transduct. Target. Ther. 2021;6:402. doi: 10.1038/s41392-021-00791-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00791-1</ArticleId><ArticleId IdType="pmc">PMC8617206</ArticleId><ArticleId IdType="pubmed">34824210</ArticleId></ArticleIdList></Reference><Reference><Citation>Goropev&#x161;ek A., Holcar M., Av&#x10d;in T. The Role of STAT Signaling Pathways in the Pathogenesis of Systemic Lupus Erythematosus. Clin. Rev. Allergy Immunol. 2017;52:164&#x2013;181. doi: 10.1007/s12016-016-8550-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-016-8550-y</ArticleId><ArticleId IdType="pubmed">27216430</ArticleId></ArticleIdList></Reference><Reference><Citation>Turkson J. STAT proteins as novel targets for cancer drug discovery. Expert Opin. Ther. Targets. 2004;8:409&#x2013;422. doi: 10.1517/14728222.8.5.409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14728222.8.5.409</ArticleId><ArticleId IdType="pubmed">15469392</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan M.H. STAT4: A Critical Regulator of Inflammation In Vivo. Immunol. Res. 2005;31:231&#x2013;242. doi: 10.1385/IR:31:3:231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/IR:31:3:231</ArticleId><ArticleId IdType="pubmed">15888914</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C., Mai H., Peng J., Zhou B., Hou J., Jiang D. STAT4: An immunoregulator contributing to diverse human diseases. Int. J. Biol. Sci. 2020;16:1575&#x2013;1585. doi: 10.7150/ijbs.41852.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.41852</ArticleId><ArticleId IdType="pmc">PMC7097918</ArticleId><ArticleId IdType="pubmed">32226303</ArticleId></ArticleIdList></Reference><Reference><Citation>Goswami R., Kaplan M.H. STAT Transcription Factors in T Cell Control of Health and Disease. Int. Rev. Cell Mol. Biol. 2017;331:123&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">28325211</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarakji I., Habbal W., Monem F. Association Between STAT4 rs7574865 Polymorphism and Rheumatoid Arthritis: Debate Unresolved. Open Rheumatol. J. 2018;12:172&#x2013;178. doi: 10.2174/1874312901812010172.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1874312901812010172</ArticleId><ArticleId IdType="pmc">PMC6210524</ArticleId><ArticleId IdType="pubmed">30505369</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Gao N., Yang L., Guo Y., Fang Y., Wang T., Xu C., Li G.F., Zhou J., Zhang Y., et al. Stat4 rs7574865 polymorphism promotes the occurrence and progression of hepatocellular carcinoma via the Stat4/CYP2E1/FGL2 pathway. Cell Death. Dis. 2022;13:130. doi: 10.1038/s41419-022-04584-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-022-04584-4</ArticleId><ArticleId IdType="pmc">PMC8826371</ArticleId><ArticleId IdType="pubmed">35136014</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng S., Zhang J., Lu G., Liu L., Deng Z. Polymorphism in STAT4 Increase the Risk of Systemic Lupus Erythematosus: An Updated Meta-Analysis. Int. J. Rheumatol. 2022;2022:5565057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9054488</ArticleId><ArticleId IdType="pubmed">35493285</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez-Serrano C. Mestizaje e Historia de la Poblaci&#xf3;n en M&#xe9;xico. Arqueologia Mexicana; Mexico City, Mexico: 1996. pp. 173&#x2013;193.</Citation></Reference><Reference><Citation>Bombardier C., Gladman D.D., Urowitz M.B., Caron D., Chang C.H., Austin A., Bell A., Bloch D.A., Corey P.N., Decker J.L., et al. Derivation of the sledai. A disease activity index for lupus patients. Arthritis Rheum. 1992;35:630&#x2013;640. doi: 10.1002/art.1780350606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780350606</ArticleId><ArticleId IdType="pubmed">1599520</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215. doi: 10.1093/nar/16.3.1215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/16.3.1215</ArticleId><ArticleId IdType="pmc">PMC334765</ArticleId><ArticleId IdType="pubmed">3344216</ArticleId></ArticleIdList></Reference><Reference><Citation>Ram&#xed;rez O.B., Rinc&#xf3;n J.F.M., Cobos R.E.B., &#xc1;vila I.A., Bello J.R. STAT4 confers risk for rheumatoid arthritis and systemic lupus erythematosus in Mexican patients. Immunol. Lett. 2016;175:40&#x2013;43. doi: 10.1016/j.imlet.2016.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2016.05.003</ArticleId><ArticleId IdType="pubmed">27178308</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagberg N., Joelsson M., Leonard D., Reid S., Eloranta M.L., Mo J., Nilsson M.K., Syv&#xe4;nen A.C., Bryceson Y.T., R&#xf6;nnblom L. The STAT4 SLE risk allele rs7574865[T] is associated with increased IL-12-induced IFN-&#x3b3; production in T cells from patients with SLE. Ann. Rheum. Dis. 2018;77:1070&#x2013;1077. doi: 10.1136/annrheumdis-2017-212794.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-212794</ArticleId><ArticleId IdType="pmc">PMC6029643</ArticleId><ArticleId IdType="pubmed">29475858</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter P., Cardoneanu A., Burlui A.M., Macovei L.A., Bratoiu I., Buliga-Finis O.N., Rezus E. Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus? Int. J. Mol. Sci. 2022;23:11788. doi: 10.3390/ijms231911788.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms231911788</ArticleId><ArticleId IdType="pmc">PMC9569651</ArticleId><ArticleId IdType="pubmed">36233087</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo B.S., Choi S.S. Introns: The Functional Benefits of Introns in Genomes. Genom. Inform. 2015;13:112. doi: 10.5808/GI.2015.13.4.112.</Citation><ArticleIdList><ArticleId IdType="doi">10.5808/GI.2015.13.4.112</ArticleId><ArticleId IdType="pmc">PMC4742320</ArticleId><ArticleId IdType="pubmed">26865841</ArticleId></ArticleIdList></Reference><Reference><Citation>Huaman M.A., Deepe G.S., Jr., Fichtenbaum C.J. Elevated Circulating Concentrations of Interferon-Gamma in Latent Tuberculosis Infection. Pathog. Immun. 2016;1:291. doi: 10.20411/pai.v1i2.149.</Citation><ArticleIdList><ArticleId IdType="doi">10.20411/pai.v1i2.149</ArticleId><ArticleId IdType="pmc">PMC5108047</ArticleId><ArticleId IdType="pubmed">27853753</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao H., Kaplan H.J., Sun D. Bidirectional Effect of IFN-&#x3b3; on Th17 Responses in Experimental Autoimmune Uveitis. Front. Ophthalmol. 2022;2:3. doi: 10.3389/fopht.2022.831084.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fopht.2022.831084</ArticleId><ArticleId IdType="pmc">PMC9521044</ArticleId><ArticleId IdType="pubmed">36188211</ArticleId></ArticleIdList></Reference><Reference><Citation>Damsker J.M., Hansen A.M., Caspi R.R. Th1 and Th17 cells. Ann. N. Y. Acad. Sci. 2010;1183:211&#x2013;221. doi: 10.1111/j.1749-6632.2009.05133.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2009.05133.x</ArticleId><ArticleId IdType="pmc">PMC2914500</ArticleId><ArticleId IdType="pubmed">20146717</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian-Ling Y., Run-Nan G., Hui Q., Yuan-Yuan S., Wang B., Zhai Z.-M. Elevated plasma levels of IL-12 and IFN-&#x3b3; in systemic lupus erythematosus. Int. J. Clin. Exp. Pathol. 2017;10:3286&#x2013;3291.</Citation></Reference><Reference><Citation>Ozmen L., Roman D., Fountoulakis M., Schmid G., Ryffel B., Garotta G. Experimental therapy of systemic lupus erythematosus: The treatment of NZB/W mice with mouse soluble interferon-&#x3b3; receptor inhibits the onset of glomerulonephritis. Eur. J. Immunol. 1995;25:6&#x2013;12. doi: 10.1002/eji.1830250103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.1830250103</ArticleId><ArticleId IdType="pubmed">7843255</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>